Ventiv Dermatology Sales Force To Promote Ranbaxy’s Isotretinoin
This article was originally published in The Pink Sheet Daily
The firms sign multi-year agreement to market Sotret. Ventiv says it has established a specialty dermatology sales force to promote the product.
You may also be interested in...
The company is seeking a partner with "strong relationships" with high-volume prescribers of overactive bladder therapies in the primary care market. Watson wants to retain Oxytrol's position in primary care despite the company's intention to shift its marketing focus to specialty care.
Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.
FDA advisory committee suggests enhancements to Roche's SMART program to better prevent pregnancies. The proposal calls for a shared brand/generic system for patient registration.